Author

John Walsh

Harvard University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Plant Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Organism:plant (other)· 1

Frequent Co-Authors

Aditya BardiaiD· 1 shared Akansha Deshpande· 1 shared Avanish MishraiD· 1 shared Charles S. Dai· 1 shared Daniel A. HaberiD· 1 shared David Tsai TingiD· 1 shared Elizabeth M. Seider· 1 shared Hannele Lindqvist‐KreuzeiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aditya BardiaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Broad-spectrum polerovirus resistance conferred by a potato TIR-NLR immune receptor

Robert Heal, He Zhao, Heekyung Ahn, Maria Sindalovskaya, John Walsh, Jan Frederik Kreuze, Hannele Lindqvist‐Kreuze, Kamil Witek, Jonathan D. G. Jones

The paper identifies Rladg, a potato TIR-NLR receptor that confers broad-spectrum resistance to poleroviruses by recognizing conserved protease structures.

bioRxiv · Jul 1, 2026 · PreprintPlant Biology

Dynamic Monitoring of Antibody Drug Conjugates Targeting TROP2 or HER2 in Breast Cancer using Circulating Tumor Cells

Avanish Mishra, Rachel O. Abelman, Quinn E. Cunneely, Victor R. Putaturo, Akansha Deshpande, Remy Bell, Elizabeth M. Seider, Katherine H. Xu, Mythreayi Shan, J. Kelly, Shih‐Bo Huang, Olivia Rieur, Justine Knape, Kaustav A. Gopinathan, Kruthika Kikkeri, , Shyamala Maheswaran

In metastatic breast cancer on TROP2- or HER2-targeting antibody-drug conjugates, early CTC disappearance or steep decline tracked response, while CTC epitope levels neither predicted benefit nor vanished at resistance.

Proceedings of the National Academy of Sciences · Jun 17, 2026Peer-reviewedCancer Biology✦ In-depth digest